Caplacizumab and immunosuppression without plasma exchange in thrombotic thrombocytopenic purpura Caplacizumab and immunosuppression without plasma exchange in thrombotic thrombocytopenic purpura Jenni Thomas / Sunday, June 22, 2025 0 400 Article rating: No rating Sunday, June 22, 2025 June 22, 2025 | Paul Coppo, M.D., Ph.D.; Saint-Antoine Hospital, Sorbonne University; Paris, France Read more
Phase 3 study of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A Phase 3 study of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A Jenni Thomas / Sunday, June 22, 2025 0 372 Article rating: No rating Sunday, June 22, 2025 June 22, 2025 | Robert Sidonio, Jr., M.D., M.Sc.; Hemophilia of Georgia Center for Bleeding and Clotting Disorders of CHOA; Atlanta, GA, U.S. Read more
Comparison of bleeding risk between rivaroxaban and apixaban in acute venous thromboembolism Comparison of bleeding risk between rivaroxaban and apixaban in acute venous thromboembolism Jenni Thomas / Sunday, June 22, 2025 0 977 Article rating: No rating Sunday, June 22, 2025 June 22, 2025 | Lana Castellucci, M.D.; University of Ottawa, Ottawa Hospital; Ottawa, ON, Canada Read more
ISTH 2025 Opening Ceremony showcases the depth and breadth of the thrombosis and hemostasis community ISTH 2025 Opening Ceremony showcases the depth and breadth of the thrombosis and hemostasis community Jenni Thomas / Sunday, June 22, 2025 0 678 Article rating: No rating Sunday, June 22, 2025 Read more
Brooke Sadler's innovative research is fueled by a family legacy Brooke Sadler's innovative research is fueled by a family legacy Jenni Thomas / Sunday, June 22, 2025 0 40 Article rating: No rating Sunday, June 22, 2025 Read more